TECVAYLI

all catalysts(0)

nothing on the calendar yet

News(10)

• Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
  In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
  biopharma_dive · 1d ago
• Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
  Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…
  biospace · 1d ago
• GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
  After inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.
  biospace · 18d ago
• GSK doubles down on Chimagen with $750M multiple myeloma wager
  GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The de…
  fiercebiotech · 18d ago
• Trailing rivals, AbbVie scores win with dual-acting myeloma drug
  The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
  biopharma_dive · 29d ago
• AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
  AbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to…
  biospace · 29d ago
• AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
  AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multip…
  fiercebiotech · 1mo ago
• Regeneron ends eye disease trial for anti-CD3 antibody following safety review
  Regeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.
  fiercebiotech · 1mo ago
• Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
  Antibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.
  fiercebiotech · 1mo ago
• Legend Biotech CEO abruptly steps down without permanent replacement
  In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
  fiercebiotech · 2mo ago